Cancer stem cells and neural stem cells: common features with different purposes

Parallels between neurogenesis and the processes contributing to brain tumor formation exist. Neural stem cells (NSCs) are quiescent cells able to self-renew and generate partially committed, highly proliferative progenitors that subsequently undergo complete differentiation into one of the three lineages composing the brain. A recognized hallmark of neural stem/progenitor cells is their ability to migrate, an essential process for recovery after brain injury [1]. The same role exerted by NSCs in the physiological context has been proposed to be played in glioblastoma (GBM) by a rare fraction of self-renewing, multipotent tumor-initiating cells called cancer stem cells (CSCs), responsible for tumor progression, maintenance, and recurrence [2,3]. This subpopulation has shown intrinsic resistance to therapy, being able to repopulate the tumor after treatment [4]. Recently, many studies have ascribed to CSCs the infiltrative property of GBM.

Cancer stem cells and invasive cells: two sides of the same coin?

The clinically distinct feature of GBM lies within its infiltrative potential, rendering complete tumor resection nearly impossible. Tumor infiltration is an extremely complex program that requires the steady supply of extracellular cues, abrogation of cell-cell interactions, and extracellular matrix (ECM) remodeling. Invading GBM cells are particularly resistant to current therapies and are often localized within the neurovascular niche, two features in common with CSCs [5].

Recent experimental data started to suggest that CSCs are responsible for GBM invasiveness. Cells enriched for the putative stem cell marker CD133 display greater migratory and invasive potential in vitro and in vivo when compared with matched CD133-negative tumor cells derived from human primary GBMs, GBM xenografts [4], and brain tumor cell lines [6-9]. We and others reported a marked upregulation of proteins involved in the processes of migration and invasion in GBM CSCs, such as different types of matrix metalloproteinases, or different members of both ADAMs (a disintegrin and metalloproteinases) and ADAMTS (ADAM with thrombospondin motifs) families [4,6-8,10]. Therefore, the highly migrating and invasive ability of GBM CSCs may be due to increased expression of proinvasive genes. Based on the findings that the GBM CSCs are more infiltrative than their differentiated descendants, a novel strategy has also been proposed to isolate and enrich CSCs from the whole tumor population by exploiting the tumor cell heterogeneity of invasiveness [11].

Cells at the leading edge of the tumor have been found to be positive for putative stem cell markers such as...
L1CAM [12], nucleostemin [13], and nestin [14-16], supporting the notion that CSCs are indeed responsible for GBM invasion. A recent paper provided new insights into the role of SOX2 as a novel determinant of the invasive and migration properties of GBM CSCs and glioma cell lines [17]. Recently, many groups have suggested that different CSCs can coexist in the same tumor. Both tumor margin and the corresponding tumor mass contain CSCs that are characterized by different stem cell marker expression, neurosphere formation ability, and in vivo tumorigenic potential [18-20]. Thus, the invasive edge of GBM may function as a new CSC niche [21]. In this scenario, the theory proposed by Brabletz and colleagues [22] about the plasticity of CSCs can also be applied to GBM: CSCs switch from a stationary and proliferative phenotype to a migratory one, and vice versa, ensuring the enlargement of the tumor core and the colonization of the neighboring normal brain tissue.

Epithelial-to-mesenchymal transition in glioblastoma? During development, embryonic cells undergo a series of trans-differentiation programs collectively assembled under the name of epithelial-to-mesenchymal transition (EMT) [23]. Interestingly, carcinoma cells exploit the same principle to drive invasion and colonization to non-adjacent tissues. EMT is a process that allows a differentiated epithelial cell, entirely settled and patterned to establish stable contacts with neighbor cells, to assume a mesenchymal cell phenotype, characterized by loss of cell-cell interactions [24], reduced cellular adhesion [25], active production of ECM proteases [26], increased cytoskeletal dynamics [27], and changes in transcription factor expression [28,29]; all of these events eventually lead to increased migration and invasion ability. Moreover, the acquisition of mesenchymal traits by cancer cells undergoing EMT has been widely reported to be associated with the acquisition of a stem cell program [30].

In GBMs, robust evidence for the existence of the EMT process is still lacking. Recently, Cheng and colleagues [34], analyzing data from The Cancer Genome Atlas (TCGA), demonstrated a strong association in GBM between an epithelial-mesenchymal expression signature, the expression of the putative stem cell marker CD44, and shortened time to recurrence following initial treatment.

The EMT program is regulated mainly by three major groups of transcription factors – the SNAI, TWIST, and Zinc-finger enhancer binding (ZEB) family members – whose upregulation promotes tumor invasiveness and has been associated with poor clinical prognosis in human cancers [28,29,35,36]. The activity of these transcription factors has been reported to be altered in GBMs. SNAI is overexpressed in GBMs [37] and is involved in the regulation of glioma cell proliferation and migration [10,38]. TWIST1 is also upregulated in GBMs, where it promotes cell invasion by the upregulation of genes such as matrix metalloproteinase-2 (MMP-2), hepatocyte growth factor (HGF), fibroblast activation protein (FAP), and SNAI [39]. The ZEB2 expression level is significantly increased in glioma tissues compared with normal brain tissues and is positively correlated with tumor grading. ZEB2 silencing reduces the expression of mesenchymal cell markers such as N-cadherin, Vimentin, and Snail and inhibits glioma cell migration and invasion [40,41]. The overexpression of all of these EMT transcription factors in GBM cell lines may occur following the activation of WNT/β-catenin pathway and results in increased in vitro cell migration and invasion [20,42].

The SNAI, TWIST, and ZEB transcription factors act by directly repressing the expression of the adhesion molecule E-cadherin, whose functional loss is considered a hallmark of EMT [43]. In parallel, there is an induction of mesenchymal markers (for example, N-cadherin and cadherin-11), reorganization of the cytoskeleton (for example, switch from cytocheratins to vimentin), and production of ECM components and metalloproteases [30]. In general, loss of E-cadherin correlates with high tumor grades and poor prognosis [44], whereas the induction of N-cadherin correlates with increased cell motility [45]. In the brain, E-cadherin expression is rare in both normal and tumoral tissues [46]. Only two recent studies argue that E-cadherin expression inversely correlates with brain tumor grade [40,47]. N-cadherin and cadherin-11 are expressed in different brain regions, including the cortex and the hippocampus, and their expression is upregulated in malignant gliomas [48]. Thus, no switch between cadherins has been described in malignant gliomas, except in some specific cases [49]. However, an alternative cadherin switch, different from the classic E-cadherin-to-N-cadherin switch described in epithelial cells, was recently described in GBMs. Lu and colleagues [50] showed Snail and N-cadherin upregulation in GBM cells, with the concomitant downregulation of T-cadherin. T-cadherin is an atypical member of the cadherin family, downregulated in different tumor types, and associated with a poorer prognosis [51]. T-cadherin expression is absent in invasive GBMs but higher in circumscribed, minimally invasive GBMs [50], and its overexpression in GBM cells inhibits proliferation and migration [52]. Consistent with these findings, Zeb-1 has been demonstrated to suppress T-cadherin expression and increase invasion in gallbladder cancer [53], thus reinforcing the role of T-cadherin in the acquisition of EMT phenotype in GBM.

Recently, GBMs have been classified by gene expression signatures in four distinct subtypes (proneural, neural,
classic, and mesenchymal) on the basis of a comprehensive analysis of The Cancer Genome Atlas (TCGA) data set [54], which are not dissimilar from the three subtypes (proneural, proliferative, and mesenchymal) described in the work of Phillips and colleagues [55]. Analysis of these data sets reveals that high expression of genes associated with mesenchyme-derived tissues is common in GBMs and associates with poor overall survival and treatment resistance [54-56]. Consistent with these findings, Joo and colleagues [57] demonstrated that CD133-negative GBM CSCs have a mesenchymal subtype genetic signature compared with CD133-positive GBM CSCs and give rise to tumors characterized by an invasive growth. Similarly, Lottaz and colleagues demonstrated that GBM CSCs positive for the putative stem cell marker CD44 [58] but negative for CD133 possess a mesenchymal gene signature and display enhanced invasive growth both in vitro and in vivo compared with CD44-negative CD133-positive cells, which instead display a proneural gene signature, limited invasiveness, and high proliferation rate [59]. In addition, several human glioma cell lines express genes associated with mesenchyme-derived tissues [60], which are reported to be involved also in migration, invasion, and EMT [61]. Notably, the ectopic coexpression of the two master regulators that define the mesenchymal subtype, CCAAT/enhancer binding protein (C/EBPβ) and signal transducer and activator of transcription 3 (STAT3), reprograms NSCs along the mesenchymal lineage, whereas their silencing in glioma cells abolishes the mesenchymal signature and reduces tumor invasiveness [62]. Similarly, the transcriptional coactivator with PDZ-binding motif (TAZ) drives the mesenchymal differentiation of GBMs: when it is overexpressed in proneural GBM CSCs as well as in NSCs, it induces mesenchymal marker expression and aberrant osteoblastic and chondrocytic differentiation, whereas its silencing in mesenchymal GBM CSCs reduces the expression of mesenchymal markers, invasion, and tumor formation [63]. It is likely that the high expression of mesenchymal genes in a subset of human GBMs can be considered to be reminiscent of the EMT program [54] or that the aberrant activation of EMT factors during gliomagenesis can trigger the mesenchymal shift in GBM [63]. All of these data suggest that GBMs share many features with EMT, but a deeper knowledge of the mechanisms driving this process is indispensable to better tackle the invasive nature of these tumors.

Unconventional molecular determinants of glioblastoma invasion

Cell motility is a complex biological process which is tightly regulated by a multitude of converging signals. Many signaling pathways regulating the stem cell compartment have been reported to be critical for triggering tumor cell migration and invasion. However, their specific involvement in glioma invasion remains poorly understood because of intricate feedback loop mechanisms and missing links between them. Given the large number of detailed reviews describing the role of different signaling pathways in tumor progression (NF-κB, notch, hedgehog-GLI, WNT/β-catenin, RTKs, and AKT are the most relevant), this review focuses on two unconventional molecular determinants of GBM invasion: doublecortin (DCX) and microRNAs.

Why should doublecortin garner cancer scientists’ interest?

The identification of single cells responsible for GBM infiltration in normal brain parenchyma is of crucial relevance. Several molecules have been used to identify invading GBM cells (for example, nestin [15,16] and vimentin [64]), but their expression could be altered by the grade of differentiation of the tumors. NSC discovery in the adult brain and the strong relationship between NSCs and CSCs have led to the consideration that these two types of cells may share common markers as well. DCX is one of them.

DCX is a microtubule-associated protein: it promotes microtubule polymerization and stability [65,66], and it is crucial for controlled cell movement, since it promotes nucleus translocation and the maintenance of a bipolar cell shape, preventing branching and nucleokinesis defects [67,68]. In humans, DCX mutations cause type I lissencephaly syndrome and subcortical laminar heterotopia, severe cortical malformations associated with mental retardation and epilepsy [69]. Knockout mouse models display milder symptoms, which are probably due to genetic redundancy with doublecortin-like (DCL) and doublecortin-like kinase (DCLK) and which become more evident when combined with mutations in LIS1, another gene involved in lissencephaly [70].

DCX is a brain-specific gene expressed in differentiating neurons during brain development [69,71], in neuroblasts, in discrete niches along the wall of the lateral ventricles, in the subgranular zone of the hippocampus, along the rostral migration stream, and in the olfactory bulbs in the adult rodent brain [72-74]. In vitro studies on neurospheres derived from adult rodent SVZ have confirmed the essential function of DCX in promoting cell migration [75].

DCX has also been proposed as a marker for migrating neuroblasts in the adult human brain [76], where it plays a crucial role in pathologic conditions in which the provision of progenitors migrating out of neurogenic areas toward the lesion is needed to replace neurons [77]. In non-injured adult mammalian brain, DCX expression outside the neurogenic areas is very rare [72,78]. Recently, DCX-positive cells have been identified in
developing and mature neurons in the cerebellar cortex of guinea pig, cat, and primate [79,80] and, to a minor extent, in cells expressing the astrocytic marker glial fibrillary protein (GFAP) [81,82]; however, these DCX+ GFAP+ cells behave as neural progenitors [82].

**Doublecortin: an appealing and promising marker for invasive glioblastoma cells**

Microtubule-associated proteins play important roles in cellular functions involving cytoskeletal rearrangement, which is one of the main features of EMT in cancer, thereby allowing cells to detach and move. Interestingly, DCX expression has been found in invasive human brain tumors, with the highest intensity at the invasive front [83], and has been proposed as a specific marker for the identification of infiltrating glioma cells [84]. Furthermore, gene expression profiling of human GBMs has revealed DCX, together with osteonectin (also known as SPARC) and semaphorin3B, as useful genetic markers to predict patient survival: the higher the expression of each of these three genes, the poorer the survival [85]. It is relevant to note that all three of these genes are involved in the regulation of cell migration, thus suggesting a direct link between tumor invasion and patient survival.

Recently, we identified RAI (SHC3/SHCC/N-SHC), a member of the family of SHC-like adaptor proteins, as a novel regulator of migration of normal and GBM stem/progenitor cells, affecting DCX protein levels [10]. RAI silencing in cancer stem/progenitor cells isolated from human GBMs reduces cell migration and invasion, both in vitro and in vivo. The rare cells still expressing RAI are localized at the tumor invasion front and express markers for both immature and migratory cells, notably DCX and OLGIG2 [86]. We always observed a significant reduction in the number of invading cells positive for DCX in all RAI-interfered GBM xenografts as well as a decreased amount of DCX in both RAI−/− normal stem/progenitor cells and RAI-interfered tumor stem/progenitor cells.

So far, only one group has reported an opposite effect of DCX on glioma cells, with exogenous DCX addition reducing CSC self-renewal [87] and tumor volume [88,89]. Such controversial results could well be related to the usage of GBM cells not expressing DCX. On the contrary, we and others reported endogenous DCX expression in both normal and cancer stem/progenitor cells [10,90].

A deeper knowledge of the molecular mechanisms regulating DCX expression could help in the identification of new targets for therapy. While there is a large amount of literature about DCX regulation in the developing brain, little is known about its regulation in adult normal and cancer brain. DCX activity is regulated by several serine-threonine kinases and phosphatases; upon phosphorylation on Ser297 residue by cyclin-dependent kinase 5, DCX affinity for microtubules decreases, promoting cell migration [91]. c-Jun N-terminal kinase (JNK), which regulates neurite extension, can phosphorylate DCX on Ser332, decreasing its affinity for tubulin and promoting cell migration [92]. Protein kinase A (PKA) and MAP/microtubule affinity-regulating kinase (MARK) regulate DCX binding affinity for microtubules, phosphorylating it on Ser47 [93]. DCX is also spatially regulated: when phosphorylated, it is expressed in the cell soma; when de-phosphorylated (likely by protein phosphatase 2A, or PP2A), it shifts to the tips of the neurites [93]. Another phosphatase acting on DCX is the tumor suppressor phosphatase and tensin homolog (PTEN) [94], which is the major inhibitor of the PI3K/AKT pathway and is frequently deleted in GBMs. A de-regulation of kinases and phosphatases is frequently observed in GBMs, therefore suggesting a possible mechanism enhancing GBM invasion. Another possible mechanism of DCX de-regulation in GBM could be linked to its transcriptional regulation. Recent studies have identified an upstream promoter region of DCX containing binding sites for LEF/TCF (lymphoid enhancer factor/T-cell factor) transcription factors [95], which are central effectors of the WNT/β-catenin pathway. This pathway is frequently altered in glioma: nuclear translocation and, therefore, activation of β-catenin have a direct impact on GBM invasion [96]. In both adult normal NSCs and CSCs isolated from human GBMs, DCX is a target of the adaptor protein RAI, which mediates multiple signaling pathways, eventually leading to metalloproteinase upregulation and GBM invasion [10] (Figure 1).

**MicroRNAs: a specific role in glioblastoma invasion**

MicroRNAs (miRNAs/miRs) are a class of small non-coding RNAs, 21 to 24 nucleotides long, which post-transcriptionally regulate gene expression by either inhibiting mRNA translation or inducing mRNA degradation, binding, via imperfect base pairing, to the 3′ untranslated region of mRNAs, allowing the targeting of a high number of mRNAs.

miRNAs play important roles in physiologic conditions as well as in various diseases, including cancer, in which they could be downregulated, acting as tumor suppressors, or upregulated, acting as oncogenes. miRNAs are involved in many aspects of gliomagenesis and GBM CSC biology: proliferation, survival, migration, invasion, and angiogenesis [97]. Moreover, recently, bioinformatics analysis of 82 gliomas indicated the association between some miRNAs and the expression of mesenchymal markers [98].

Table 1 depicts the most intriguing ones found to be directly involved in the GBM invasion process, suggesting interesting putative targets for GBM therapy. Of note, the majority of the literature analyzes the role of miRNAs in GBM infiltration through experiments using glioma.
cell lines, and very little experimental evidence on the role of miRNAs in migration and invasion of GBM CSCs is available. Given the contribution of CSCs to GBM invasiveness (highlighted in the previous section), we believe that further validation of the properties of specific miRNAs regulating migration and invasion in CSCs is essential.

**MicroRNAs acting as oncogenes in glioblastoma**

TWIST1, a transcription factor involved in EMT, has been shown to bind the upstream portion of the miR-10 hairpin region, modulating its expression [99]. MiR-10b, as well as TWIST [100], is overexpressed in glioma samples, with the highest peaks in GBM as compared with low-grade astrocytomas, and induces glioma cell invasion in vitro by decreasing HOXD10 (homeobox D10) protein levels, which in turn control MMP-14 and uPAR (urokinase receptor) expression, resulting in their upregulation [101]. Other metalloproteinases, such as MMP-2, are upregulated in cancer as a consequence of the repression of MMP inhibitors, such as TIMP3 (metalloproteinase inhibitor 3) and RECK, which are themselves direct targets of miR-21, found to be overexpressed in GBM, thus promoting glioma invasion and angiogenesis [102]. Moreover, analysis of miRNAs in gliomas belonging to different grades associated high miR-21 with poor patient survival [103].

Overexpression of the miR-221/222 cluster in malignant glioma cells results in the reduced expression of the tumor suppressor connexin 43 (Cx43), leading to the reduction of gap junction intercellular communication and, as a result, to an increase in proliferation and invasion of glioma cells [104]. In a highly intricate regulatory system, other important transcription factors, involved in cancer development when de-regulated, have been linked to miRNAs, such as NF-κB and c-Jun. These factors can induce glioma cell proliferation and invasion by promoting overexpression of miR-221/222 [105], resulting in the repression of the cell cycle inhibitor p27kip1 and in the activation of the AKT pathway leading to, among several targets, MMP activation [106,107].

**MicroRNAs acting as tumor suppressors in glioblastoma**

Mir-7 blocks cancer invasion, proliferation, and survival. It has been found strongly downregulated in GBM
Table 1. Biological functions of the different microRNAs associated with glioblastoma invasion

| microRNA | Biological function | Reference |
|----------|---------------------|-----------|
| miR-7    | Downregulated in GBM. Acts as a tumor suppressor in GBM, preventing GBM CSC invasion, proliferation, and survival by repressing EGFR and its downstream pathway AKT on one side and FAK and the production of MMP-2 and MMP-9 on the other side. | [108,109] |
| miR-10b  | Acts as oncogene; it is overexpressed in glioma samples. Induces glioma cell invasion in vitro by decreasing HOXD10 protein levels, which in turn control MMP-14 and uPAR expression, resulting in their upregulation. | [101] |
| miR-21   | Acts as oncogene; it is overexpressed in GBM, where it represses the MMP inhibitors TIMP3 and RECK, thus resulting in metalloproteinase MMP-2 upregulation, promoting glioma invasion and angiogenesis. High levels of this miR are associated with poor patient survival. | [102,103] |
| miR-23b  | Acts as a tumor suppressor and is downregulated at the invasive edge in GBM. Pyk2, whose expression is higher in high-grade gliomas, is one of its direct targets. | [110] |
| miR-34a  | Acts as a tumor suppressor and is downregulated in human glioma tumors as compared with normal brain. Its overexpression exerts a suppressive effect in GBM CSCs by inhibiting proliferation and migration while inducing differentiation (Guessous et al. [111]). | [111] |
| miR-101  | Acts as a tumor suppressor and is downregulated in GBM. Its target EZH2, a histone methyl transferase belonging to the Polycomb Group of proteins, is therefore overexpressed, promoting cell migration, neo-angiogenesis, and cell growth. | [112] |
| miR-124a | Acts as a tumor suppressor and is downregulated in GBM, in association with a shorter patient survival. In vitro, it negatively regulates cell migration and invasion through the negative regulation of its direct targets IQGAP1, laminin 1, and integrin β1. | [113,114] |
| miR-137  | It is downregulated in GBM and acts as a tumor suppressor. In vitro, it negatively regulates glioma cell migration, invasion, and proliferation, reducing MMP-9 levels and directly targeting Cox-2 expression. | [116] |
| miR-145  | Not clear yet. Suggested as pro-invasive oncogene by Koo et al. [124] but as a tumor suppressor inhibiting glioma cell invasion by Lee et al. [123]. | [123,124] |
| miR-146b | Acts as a tumor suppressor. Represses both EGFR and MMP expression, reducing glioma cell migration and invasion. | [117,118] |
| miR-195  | Acts as a tumor suppressor. It is downregulated in GBM, where it promotes proliferation and invasion through deregulation of its targets E2F3 and cyclin D3, respectively. | [119] |
| miR-221/222 | Act as oncogenes: their overexpression in glioma cells causes downregulation of connexin 43, a major component of gap junctions, inducing cell proliferation and invasion. Their overexpression is induced by de-regulated NF-κB and c-Jun transcription factors, resulting in the repression of the cell cycle inhibitor p27Kip1 and in the activation of the Akt pathway leading to, among several targets, MMP activation and thus promoting glioma cell proliferation and invasion. | [104-107] |
| miR-302/367 | Act as a tumor suppressor: when expressed, they suppress stemness gene signature, CSC self-renewal, infiltration, and tumorigenic capacity through a drastic inhibition of the CXCR4 pathway (Fareh et al. [120]). | [120] |
| miR-410  | Acts as tumor suppressor in GBM, decreasing cell proliferation and invasion by targeting MET and consequently AKT signaling and MMP-9 levels. | [122] |

AKT, serine/threonine-specific protein kinase; CSC, cancer stem cell; EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; GBM, glioblastoma; HOXD10, homeobox D10; miRNA/miR, microRNA; MMP, matrix metalloproteinase; NF-κB, nuclear factor-kappa-B; RECK, Reversion-inducing cysteine-rich protein with Kazal motifs precursor; TIMP, tissue inhibitors of metalloproteinase; uPAR, urokinase-type plasminogen activator receptor.

samples compared with normal brain, and in vivo experiments showed that it inhibits GBM CSC proliferation and invasion by signaling on different targets: it directly inhibits the EGFR expression and therefore the downstream AKT pathway [108] and directly inhibits focal adhesion kinase (FAK), which has a role in the production of metalloproteinases such as MMP-2 and MMP-9 [109]. MiR-23b is downregulated at the invasive edge of human GBM samples as opposed to the tumor core and suppresses glioma cell migration and invasion in in vitro and ex vivo experiments. It directly targets Pyk2 (proline-rich tyrosine kinase 2), the expression of which correlates positively with tumor grade and is known to promote GBM cell migration and invasion [110]. MiR-34a is downregulated in human glioma tumors as compared with normal brain. When overexpressed in GBM CSCs, it exerts a suppressive effect by inhibiting proliferation and migration while inducing differentiation [111].

MiR-101, when downregulated in GBM, causes not only cell migration and invasion but also neo-angiogenesis and cell growth [112]. MiR-124a expression was
found to be downregulated in a wide range of GBM samples, in association with shorter patient survival. *In vitro* studies showed that it negatively regulates cell migration and invasion, through the negative regulation of its direct targets, IQ motif-containing GTPase-activating protein 1 (IQGAP1), laminin 1 (LAMC1), and integrin β1 (ITGB1) [113]. Recently, miR-124 was shown to inhibit glioma cell invasion and stem cell traits through SNAI2, which is often upregulated in glioma and enriched in the stem cell population [114]. The fact that miR-124a also promotes neuronal differentiation, antagonizing the transcriptional repressor RE1 silencing transcription factor (REST) [115], is even more promising for the therapeutic use of miR-124a, which could block GBM invasion and induce tumor cell differentiation at the same time. MiR-137 expression inversely correlates with glioma grade. *In vitro* experiments on glioma cell lines showed that it inhibits migration and invasion, decreasing MMP-9 levels, and proliferation, directly targeting Cox-2, which is more expressed in high-grade tumors and correlates with poorer prognosis [116]. MiR-146b represses both *EGFR* and *MMP* expression, reducing glioma cell migration and invasion [117,118]. MiR-195 has been found to be strongly downregulated in human GBM cells, causing upregulation of its targets E2F3 and cyclin D3, thus promoting glioma cell proliferation and invasion, respectively [119].

The cluster miR-302/367 is induced during serum-mediated stemness suppression in GBM CSCs; when expressed, it suppresses stemness gene signature, CSC self-renewal, infiltration, and tumorigenic capacity through a drastic inhibition of the CXCR4 pathway [120]. The blockage of CXCR4 signaling leads to a drastic repression of the sonic hedgehog (SHH)-GLI-NANOG network, which has been demonstrated to regulate self-renewal and expression of the embryonic stem cell-like signature [121]. MiR-410 was recently characterized as a direct regulator of MET (the receptor for hepatocyte growth factor receptor, or HGF), downregulating MET-induced AKT signal transduction, with a negative effect on cell proliferation and invasion, decreasing P-AKT and MMP-9 levels [122].

Contrasting pieces of evidence have recently been reported for miR-145. MiR-145 has been characterized as a possible tumor suppressor gene in GBM, negatively acting on the expression of several metastasis-related genes, such as *PLAUR* (plasminogen activator urokinase receptor), *SP0CK3*, *ADAM22*, *SLC7A5* (solute carrier family 7 member 5), and *FASCNI*, and inhibiting glioma cell invasion *in vitro* [123]. On the other hand, miR-143 and -145 (which are expressed by the same genetic locus) have been suggested as possible oncogenes and, in particular, have been shown to exert pro-invasive function in *in vitro* experiments [124].

**Conclusions and perspectives**

Highly diffuse and infiltrative growth is an important effector of GBM pathogenesis and represents the main limitation in the feasibility of current treatments. In recent years, the molecular players and the signaling cascades triggering the motility and invasion of glioma cells have been widely investigated in order to increase our understanding of the mechanism of glioma spreading and eventually improve the survival of patients with glioma. Following the classification of gliomas in subtypes based upon molecular signatures [54,55], a similar approach based upon microRNA expression has been proposed. Gene expression profile analysis of gliomas revealed a capacity to effectively distinguish GBMs from low-grade gliomas, which overexpressed different classes of microRNAs [125], but also to establish a signature able to predict the survival of patients with GBM on the basis of the expression of 10 microRNAs [126]. In this scenario, the analysis of both GBM molecular signatures and miRNA expression signatures may contribute to cancer diagnosis, prognosis, patient stratification, and a more personalized treatment.

This review lends further weight to these findings, highlighting the role of GBM CSCs as novel determinants of the infiltrative behavior of GBMs. Of further interest, specific effectors implicated in the process of migration and invasion (that is, EMT-associated factors, DCX, and microRNAs) are known to be associated with CSC biology. Given the resistance of CSCs to traditional therapies, approaches designed to target CSCs and their effectors will represent exciting therapeutic targets effective in suppressing the CSC-mediated GBM invasion.

Recently, GBMs have been shown to contain microvesicles carrying angiogenic proteins and inhibitors of MMPs, of *EGFRvIII* mRNA, and of miRNA-21, responsible for GBM invasion [102,127]. These microvesicles have been used as biomarkers since they carry brain tumor-specific antigens and cytokines and are present in the serum of patients with high-grade glioma [128]. Furthermore, these microvesicles could be exploited as possible vehicles for innovative anti-miR therapy of GBM since short-hairpin RNAs have been efficiently delivered to the brain by systemic injection [129]. The possibility to limit the GBM infiltrative component is likely to have a large impact on therapies designed to block tumor progression.

**Abbreviations**

CSC, cancer stem cell; DCX, doublecortin; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; GBM, glioblastoma; miRNA/miR, microRNA; MMP, matrix metalloproteinase; NSC, neural stem cell.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

All authors contributed equally to the manuscript. BO prepared the figure and the table. All authors read and approved the final manuscript.
Acknowledgments

The work was supported by the Association for International Cancer Research (08-0562 to JP).

Published: 28 February 2013

References

1. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Activation of the DNA damage response. Cancer Cell 2004, 11:119-123.

2. Imitola J, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

3. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: The epithelial-mesenchymal transition generates cells with properties of glioblastoma stem cells. Cancer Cell 2011, 17:82-93.

4. Imitola J, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

5. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

6. Imitola J, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

7. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

8. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

9. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

10. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

11. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

12. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

13. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

14. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.

15. Imitola J, Raddassi K, Park KI, Nieland RE, Dewhirst MW, Bigner DD, Rich JN: Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
Smad interacting protein 1 (SIP1) in glioma. J. Neurooncol 2010, 97:225-232.

41. Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W, Zhen Y, Zhou Y, Chen Y, Mai C, Liu Z, Fang W. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One 2012, 7:e38842.

42. Kahler JD, Maciacyk D, Dooostkam S, Orr BA, Bogiel T, Reithmeier P, Prinz M, Schubert J, Niedermann G, Brabletz T, Eberhart CG, Ninkahgh G. Maciacyk J. Activation of canonical Wnt/beta-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett 2012, 325:42-53.

43. Medici D, Hay ED, Olsen BR. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T cell factor-4-dependent expression of transforming growth factor-beta. Mol Cell Biol 2008, 19:4875-4887.

44. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998, 153:333-339.

45. Suyama K, Shapiro I, Guttman M, Hazan R. B. Ortensio N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. Transcriptional and epigenetic regulation of the malignant glioma phenotype. Cancer Cell 2010, 17:295-304.

46. Asano K, Duntsch CD, Zhou Q, Weimar JD, Bolderton D, Robertson JH. Pourmotabbed T. Correlation of N-cadherin expression in high grade gliomas with tissue invasion. J Neurooncol 2004, 70:3-15.

47. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, Reithmeier P. Development of an aggressive brain tumor phenotype. Cancer Cell 2002, 2:301-314.

48. Motta FJ, Valera ET, Luque-Etortero AK, Queruez RG, Neder L, Scordelli CA, Machado T, Carlotti-Junior GG, Marie SK, Tone LG. Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res 2008, 7:295-304.

49. Suh J, Lee CC, Shih XL, Huang DY, Ma HL, Lai JH, Wei HW, Lee HM. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neur Oncol 2010, 12:58-70.

50. Moores CA, Perединiet M, Francis F, Chelly J. Houdusse A, Milligan RA. Mechanism of microtubule stabilization by doublecortin. Mol Cell 2004, 14:833-839.

51. Moores CA, Perediniet M, Kappeler C, Kain S, Drummond D, Perkins SJ, Chelly J, Cross R, Houdusse A, Francis F. Distinct roles of doublecortin modulating the microtubule cytoskeleton. Emb J 2006, 26:4448-4457.

52. Kozumi H, Higginbotham H, Poon T, Tanaka T, Brinkman BC, Gleeson JG. Doublecortin maintains bipolar shape and nuclear translocation during migration in the adult forebrain. Nat Neurosci 2006, 9:77-86.

53. Kappeler C, Saillour Y, Baudoin JP, Tsuzuki C, Alvarez C, Houbon C, Gaspar P, Hamard G, Chelly J, Merlin C, Francis F. Branching and nucleokinesis defects in migrating interneurons derived from doublecortin knockout mice. Hum Mol Genet 2006, 15:1387-1400.

54. de Portes V, Pinard JM, Billuart P, Vinet MC, Kouklouf A, Carrie A, Geloet A, Dupuis E, Motte J, Bernwald-Netter Y, Catala M, Kahn A, Beldjord C, Chelly J. A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome. Cell 1998, 92:51-61.

55. Pampalone T, Youn YH, Yingling J, Hirotsume S, Wynshaw-Boris A. Novel embryonic neuronal migration and proliferation defects in Dcx mutant mice are exacerbated by Lis1 reduction. J. Neurosci 2010, 30:3002-3012.

56. Francis F, Kouklouf A, Boucher D, Chelly J, Sapor A, Vinet MC, Fricourt G, McDonnell N, Reiner O, Kahn A, McConnell SK, Bernwald-Netter Y, Denoullet J, Chelly J. Doublecortin is a developmentally regulated, microtubule-associated protein expressed in migrating and differentiating neurons. Neuro 1999, 23:247-256.

57. Brown JP, Couillard-Despres S, Cooper-Kuhn CM, Billuart P, Vinet MC, Kouklouf A, Carrie A, Geloet A, Dupuis E, Motte J, Bernwald-Netter Y, Catala M, Kahn A, Beldjord C, Chelly J. A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome. Cell 1998, 92:51-61.
guinean pig cerebral cortex: partial colocalization with mature interneuron markers. Exp Neurol 2009, 211:271-282.

80. Cai Y, Kiong K, Chu Y, Luo DW, Luo XG, Yuan XY, Struble RG, Clough RW, Spencer DD, Williamson A, Kordower JH, Tapilyo P, Yan KX. Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol 2009, 216:342-356.

81. Verweer RW, Sluiter AA, Balseara RA, Baayen JC, Nospe DP, Driven CM, Wouda J, van Dam AM, Lucassen PJ, Swaab DF. Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin. Brain, 2007, 130 (Pt 12):3321-3335.

82. Bioch J, Kiefer M, Sadeghi Y, Rouiller EM, Redmond DE Jr, Brunet JF. Doublecortin-positive cells in the adult primate cerebral cortex and possible role in brain plasticity and development. J Comp Neurol 2011, 519:775-789.

83. Dao MC, Smith TW, Litofsky NS, Hsieh CC, Ross AH. Doublecortin is preferentially expressed in invasive human brain tumors. Acta Neuropathol 2011, 120:472-480.

84. Masu K, Kawatari SY, Suzuki SO, Iwaki T. Involvement of doublecortin in cellular signaling mediating self-renewal and differentiation of brain tumor stem cells. Cancer Sci 2011, 102:1350-1357.

85. Rich JN, Hans C, Jones B, Isberg ES, McLendon RE, Rasheed BK, Dobra A, Tanaka T, Serneo FF, Tseng HC, Kulkarni AB, Tsai LH, Gleeson JG. Cai Y, Xiong K, Chu Y, Luo DW, Luo XG, Yuan XY, Struble RG, Clough RW, Dressman HK, Bigner DD, Nevins JR, West M. Doublecortin and smoothened signaling pathway control glioma stem cell self-renewal. Brain Tumor Pathol 2008, 25:1-7.

86. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M. Doublecortin on self-renewal and differentiation in brain tumor stem cells. Cancer Res 2008, 68:1451-1459.

87. Schaar BT, Kinoshita K, McConnell SK. Alp ha-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of beta-catenin and mesenchymal marker gene expression in glioblastoma. Cancer Res 2005, 65:4051-4058.

88. Santra M, Zhang X, Santra S, Jiang F, Chopp M. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells. Neoplasia 2007, 9:824-837.

89. Liu L, He F, Litofsky NS, Rech LT, Ross JH. Profiling of genes expressed by PTEN haploinsufficient nuclear precursor cells. Mol Cell Neurosci 2003, 24:1051-1061.

90. Li L, Cai L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, Mir-l137 is frequently down-regulated in glioblastoma and is a negative regulator of glioma. Cancer Invest 2012, 30:1024-1030.

91. Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, Sagata N, Murata H, Kuga D, Amano T, Nakamizono A, Sarafian T. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol 2012, 14:1153-1162.

92. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C, MIR-146B-5P suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 2010, 28:1024-1030.

93. Zhang QQ, Xu H, Huang MB, Ma LW, Huang QJ, Yao Q, Zhou H, Qu LH. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol 2012, 14:1153-1162.

94. Faehre M, Tauchi L, Viroille V, Debruyne D, Alnairac E, de-la-Forest Divonne S, Paquis P, Peyrat-Deaunoue Q, Krahe KH, Chniewiess H, Viroille T. The miR-302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CCK4 repression and consequent disruption of the SHH/GLI-NANOG network. Cell Death Differ 2012, 19:232-244.

95. Zbinden M, Duquen A, Lorente-Tirgus A, Ngwabty SN, Borges I, Ruiz A. Litauba A.
NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. *Embo J* 2010, 29:2659-2674.

122. Chen L, Zhang J, Feng Y, Li R, Sun X, Du W, Piao X, Wang H, Yang D, Sun Y, Li X, Jiang T, Kang C, Li Y, Jiang C. MiR-410 regulates MET to influence the proliferation and invasion of glioma. *Int J Biochem Cell Biol* 2012, 44:1711-1717.

123. Lee SJ, Kim SJ, Seo HH, Shin SR, Kim D, Park CS, Kim KT, Kim YH, Jeong JS, Kim IH. Over-expression of miR-145 enhances the effectiveness of HSVtk gene therapy for malignant glioma. *Cancer Lett* 2012, 320:72-80.

124. Koo S, Martin GS, Schulz KJ, Ronck M, Toussaint LG. Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. *BMC Cancer* 2012, 12:143.

125. Lages E, Guttin A, El Atifi M, Ramus C, Ipsas H, Dupre I, Rolland D, Salon C, Godfraind C, Defraipont F, Dhobb M, Pelletier L, Wion D, Gay E, Berger F, Issartel JP. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. *PLoS One* 2011, 6:e20600.

126. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. *PLoS One* 2011, 6:e17438.

127. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol* 2008, 10:1470-1476.

128. Graner MW, Alzate O, Dechtkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bignier DD. Proteomic and immunologic analyses of brain tumor exosomes. *FASEB J* 2009, 23:1541-1557.

129. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol* 2011, 29:341-345.

doi:10.1186/scrt166

Cite this article as: Ortensi B, et al. Cancer stem cell contribution to glioblastoma invasiveness. *Stem Cell Research & Therapy* 2013, 4:18.